ClinicalTrials.gg
Not yet recruitingNCT06836375Updated Aug 19, 2025

Pilot Study for the Application of Low Power External Bioelectronic Devices in the Diagnosis of Bronchial Asthma.

An observational study in Asthma Bronchiale, sponsored by Acurable Ltd.. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-19.

Sponsored by Acurable Ltd. · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 222 studies in Asthma with a site in Spain — 30 open to participants now, 42 under way, 13 of them phase 3. Asthma · Spain.

Planned enrollment
41st of 52
50 · median 218
Started
2025
with 12 others
Observational
52 of 222
8 open now
Primary completion
2026-02
later than 8 of 41 live
Registered
205th of 222
by date

Among the 222 studies in Asthma with a site in Spain, this one is the 41st largest by planned enrollment of the 52 observational ones that give a count, is one of 13 that started in 2025, is one of 52 observational ones, reaches primary completion later than 8 of the 41 other live ones, and was the 205th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

30 of the 222 studies in Asthma with a site in Spain are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 222 studies in Asthma with a site in Spain, or all of them as a file.
02

Study summary

The objective of this study is to detect the acoustic signals generated by the respiratory system on asthma patients using an acoustic sensor and retrospectively use these signals to identify the characteristics that differentiate patients with asthma and healthy subjects.

Read the detailed description

The objective of this project is to detect acoustic signals generated by the respiratory system in patients with asthma using the acoustic sensor; and then, retrospectively, to use these signals to carry out signal processing research, with the aim of trying to identify signal characteristics that can be used to differentiate asthma patients from people who do not have the disease.

The hypothesis, therefore, is that it is possible to target through external smart bioelectronic devices and wireless connectivity (wearables) the initial signals of the pathophysiology of bronchial asthma and differentiate them from the signals of the normal respiratory physiology of a healthy individual.

Similarly, detection of such signals would not only be useful for asthma diagnosis but also for monitoring and early detection of exacerbations before they can be detected by the usual respiratory functional tests.

The patients will first visit the asthma unit where the diagnostic tests will be undertaken. Then the subjects will take the acoustic sensor home with them and wear it during sleep for at least two weeks.

03

Conditions studied

  • Asthma Bronchiale

Browse trials for

Keywords

  • Asthma
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients from or referred to the asthma unit in the hospital Virgen del Rocio in Seville, Spain

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged >= 18 and \< 65.
  • Ability to access applications on mobile device, technical understanding and minimal technological skills
  • Subject has provided and is willing to comply with the study procedures.

Exclusion criteria

Exclusion Criteria:

  • Subject does not consent to the study
  • Subject does not comply with inclusion criteria
  • Subject has a known allergy to medical adhesives
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with Bronchial asthma

    Patients with a diagnosis of bronchial asthma, under follow-up by the Asthma Unit.

    Diagnostic Test: Spirometry test with bronchodilation · Diagnostic Test: Methacholine challenge · Diagnostic Test: impulse oscillometry · Other: Measurement of the exhaled FeNO fraction

  • Patients referred for consultation

    Patients referred for consultation due to clinical suspicion of bronchial asthma.

    Diagnostic Test: Spirometry test with bronchodilation · Diagnostic Test: Methacholine challenge · Diagnostic Test: impulse oscillometry · Other: Measurement of the exhaled FeNO fraction

Interventions

  • Diagnostic testSpirometry test with bronchodilation

    this test measures how much air you can breathe in and out of your lungs, as well as how easily and fast you can then blow the air out of your lungs

  • Diagnostic testMethacholine challenge

    test used to diagnose asthma where the patient breaths in methacholine

  • Diagnostic testimpulse oscillometry

    test that uses sound waves to measure how much resistance there is to the normal movement of air in and out of your lungs when you are breathing at rest

  • OtherMeasurement of the exhaled FeNO fraction

    Measure the level of nitric oxide in parts per billion (PPB) in the air the patient slowly exhales

06

What researchers measure

Primary outcomes

  1. Acoustic respiratory signals

    Acoustic signals during the tests performed for asthma diagnosis and while the subjects sleep for at least two weeks.

    Time frame: During the diagnostic tests performed and during the night studies performed by the participant for at least two weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Feb 2026, 5 months later.

Of 90 industry-sponsored observational studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 58. This study's planned 5 months is below that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2025
First posted
Feb 20, 2025
StartEst.
Sep 27, 2025
Primary completionEst.
Feb 27, 2026
CompletionEst.
Feb 27, 2027
Last update
Aug 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06836375
Lead sponsor
Acurable Ltd.
Responsible party
Sponsor
First posted
Feb 20, 2025
Start date
Sep 27, 2025 (estimated)
Primary completion
Feb 27, 2026 (estimated)
Completion
Feb 27, 2027 (estimated)
Last update
Aug 19, 2025

Study contacts

Orsina Dessi
Contact
orsina@acurable.com
+44 7721877020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion